This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Obesity Science & Innovation USA (OSI USA)
September 23-24, 2026 | Part of Biotech Week Boston
Hynes Convention CenterBoston, United States
Book Now
Menu
Book

Luba Greenwood
CEO at Mwyngil Therapeutics
Speaker

Agenda Sessions

  • Keynote Panel: Redefining Healthy Weight-Loss: Innovations, Challenges, and Future Opportunities

    , 09:10
    View Session

  • MW-401: Best-in-Class Selective GPR75 Antagonist for Obesity and Metabolic Disorders

    , 10:50
    View Session

At this event

Prev
Next
Laura Holberger
Associate Director, R&D External Innovation Partners
Novo Nordisk

See Luba at Obesity Science & Innovation USA (OSI USA)

Book Now